Table 1. Baseline characteristics of the patients.
| Mean±SD or median (IQR) | Reference ranges | |
|---|---|---|
| Age (years old) | 68.4±7.34 | |
| Gender | Male: Female = 17:17 | |
| Cause of renal failure, n (%) |
|
|
| Hemodialysis duration (month) | 29.5 (17–65.5) | |
| BMI (kg/m2) | 21.8±3.3 | |
| Diabetes Mellitus, n (%) | 14 (41.2) | |
| Hypertension, n (%) | 32 (94.1) | |
| Ischemic heart disease, n (%) | 6 (17.6) | |
| Peripheral arterial disease, n (%) | 8 (23.5) | |
| Calcium Channel Blocker use, n (%) | 16 (47.1) | |
| RAS inhibitor (ACE-I, ARB) use, n (%) | 20 (58.8) | |
| Active form vitamin D use, n (%) | 26 (76.5) | |
| Pre dialysis systolic BP(mmHg) | 152±23 | |
| Pre dialysis diastolic BP(mmHg) | 77±11 | |
| Pulse pressure(mmHg) | 74.4±17.2 | |
| Total Protein(g/dl) | 6.40±0.58 | 6.4–8.3 |
| Albumin(g/dl) | 3.80±0.34 | 3.8–5.2 |
| Corrected Ca (mg/dl) | 8.98±0.48 | 8.3–10.4 |
| IP (mg/dl) | 5.71±1.35 | 2.7–4.5 |
| Ca×IP (mg2/dl2) | 51.3±12.4 | |
| Intact PTH (pg/ml) | 177.1±122.4 | 8.7–79.5 |
| Hemoglobin(g/dl) | 11.0±1.2 | 11.0–15.6 |
| Platelet (×104/μl) | 17.6±5.5 | 12.4–30.5 |
| hs-CRP (mg/dl) | 0.11(0.04–0.38) | <0.5 |
| Log hs-CRP | -0.92±0.6 | |
| Fibrinogen (mg/dl) | 366.2±68.8 | 150–400 |
| β2microgloblin (mg/l) | 25.3±6.5 | 0.9–1.9 |
| tHcy (μmol/l) | 27.6(20.5–52.7) | 5.1–11.7 |
| Log tHcy | 1.55±0.32 |
Abbreviations are; BMI, body mass index; RAS, renin-angiotensin system; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin type2 receptor blocker; BP, blood pressure; Ca, calcium; IP, inorganic phosphate; PTH, parathyroid hormone; hs-CRP, hypersensitive C-reactive protein; tHcy, total homocysteine; Log tHcy, logarithmic total homocysteine.